Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1 Ureteral Neoplasms 1

Interventions

pembrolizumab 182 Magnetic Resonance Spectroscopy 163 Specimen Handling 135 enzalutamide 126 Nivolumab 124 Gemcitabine 99 Docetaxel 96 Radiosurgery 92 Prednisone 85 Androgen Antagonists 82 Abiraterone Acetate 81 Radiotherapy 75 apalutamide 68 Cisplatin 65 darolutamide 63 Ipilimumab 63 Biopsy 60 abiraterone 58 Carboplatin 56 cabozantinib 55 Leuprolide 53 enfortumab vedotin 49 Radiation 48 Pluvicto 45 Standard of Care 44 atezolizumab 40 Surveys and Questionnaires 39 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 37 X-Rays 37 avelumab 35

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Plasmapheresis × Genitourinary × 1 year × Clear all

NCT07087860 2026-05-08

RECIPE-B1

Mayo Clinic

Phase 2 Recruiting

Urinary Bladder Neoplasms, Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡